{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Geron Corporation"},"Symbol":{"label":"Symbol","value":"GERN"},"Address":{"label":"Address","value":"919 EAST HILLSDALE BOULEVARD,SUITE 250, FOSTER CITY, California, 94404, United States"},"Phone":{"label":"Phone","value":"+1 650 473-7700"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug."},"CompanyUrl":{"label":"Company Url","value":"https://www.geron.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrew J. Grethlein","title":"Chief Operating Officer & Executive Vice President"},{"name":"Faye Feller","title":"Chief Medical Officer & Executive Vice President"},{"name":"John A. Scarlett","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}